Hector H Garcia1,2, Yesenia Castillo2, Isidro Gonzales1, Javier A Bustos2, Herbert Saavedra1, Louis Jacob3, Oscar H Del Brutto4, Patricia P Wilkins5, Armando E Gonzalez6, Robert H Gilman2,7. 1. Cysticercosis Unit, Department of Transmissible Diseases, Instituto Nacional de Ciencias Neurologicas, Lima, Peru. 2. Department of Microbiology, School of Sciences, Universidad Peruana Cayetano Heredia, Lima, Perú. 3. Faculty of Medicine, University of Paris, Paris, France. 4. School of Medicine, Universidad Espíritu Santo-Ecuador, Guayaquil, Ecuador. 5. Parasitology Services, Marathon, FI, USA. 6. School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos, Lima, Perú. 7. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
OBJECTIVE: To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa® and Ridascreen® , for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentil-lectin purified glycoprotein antigens). METHODS: Archive serum samples from patients with viable NCC (n = 45) or resolved, calcified NCC (n = 45), as well as sera from patients with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45), were evaluated for cysticercosis antibody detection using two ELISA kits, Novalisa® and Ridascreen® . All NCC samples had previously tested positive, and all samples from heterologous infections were negative on LLGP-EITB for cysticercosis. Positive rates were calculated by kit and sample group and compared between the two kits. RESULTS: Compared to LLGP-EITB, the sensitivity of both ELISA assays to detect specific antibodies in patients with viable NCC was low (44.4% and 22.2%), and for calcified NCC, it was only 6.7% and 4.5%. Sera from patients with cystic hydatid disease were highly cross-reactive in both ELISA assays (38/45, 84.4%; and 25/45, 55.6%). Sera from patients with hymenolepiasis cross-reacted in five cases in one of the assays (11.1%) and in only one sample with the second assay (2.2%). CONCLUSIONS: The performance of Novalisa® and Ridascreen® was poor. Antibody ELISA detection cannot be recommended for the diagnosis of neurocysticercosis.
OBJECTIVE: To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa® and Ridascreen® , for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentil-lectin purified glycoprotein antigens). METHODS: Archive serum samples from patients with viable NCC (n = 45) or resolved, calcified NCC (n = 45), as well as sera from patients with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45), were evaluated for cysticercosis antibody detection using two ELISA kits, Novalisa® and Ridascreen® . All NCC samples had previously tested positive, and all samples from heterologous infections were negative on LLGP-EITB for cysticercosis. Positive rates were calculated by kit and sample group and compared between the two kits. RESULTS: Compared to LLGP-EITB, the sensitivity of both ELISA assays to detect specific antibodies in patients with viable NCC was low (44.4% and 22.2%), and for calcified NCC, it was only 6.7% and 4.5%. Sera from patients with cystic hydatid disease were highly cross-reactive in both ELISA assays (38/45, 84.4%; and 25/45, 55.6%). Sera from patients with hymenolepiasis cross-reacted in five cases in one of the assays (11.1%) and in only one sample with the second assay (2.2%). CONCLUSIONS: The performance of Novalisa® and Ridascreen® was poor. Antibody ELISA detection cannot be recommended for the diagnosis of neurocysticercosis.
Authors: Yeuk-Mui Lee; Sukwan Handali; Kathy Hancock; Sowmya Pattabhi; Victor A Kovalenko; Andrew Levin; Silvia Rodriguez; Sehching Lin; Christina M Scheel; Armando E Gonzalez; Robert H Gilman; Hector H Garcia; Victor C W Tsang Journal: Am J Trop Med Hyg Date: 2011-04 Impact factor: 2.345
Authors: Sukwan Handali; Armando E Gonzalez; Kathy Hancock; Hector H Garcia; Jacquelin M Roberts; Robert H Gilman; Victor C W Tsang Journal: Am J Trop Med Hyg Date: 2004-09 Impact factor: 2.345
Authors: John Noh; Silvia Rodriguez; Yeuk-Mui Lee; Sukwan Handali; Armando E Gonzalez; Robert H Gilman; Victor C W Tsang; Hector H Garcia; Patricia P Wilkins Journal: J Clin Microbiol Date: 2014-02-19 Impact factor: 5.948
Authors: Christina M Coyle; Siddhartha Mahanty; Joseph R Zunt; Mitchell T Wallin; Paul T Cantey; A Clinton White; Seth E O'Neal; Jose A Serpa; Paul M Southern; Patricia Wilkins; Anne E McCarthy; Elizabeth S Higgs; Theodore E Nash Journal: PLoS Negl Trop Dis Date: 2012-05-29
Authors: M A Gómez-Morales; T Gárate; J Blocher; B Devleesschauwer; G S A Smit; V Schmidt; M J Perteguer; A Ludovisi; E Pozio; P Dorny; S Gabriël; A S Winkler Journal: Eur J Clin Microbiol Infect Dis Date: 2017-07-01 Impact factor: 3.267
Authors: Veronique Dermauw; Steven Van Den Broucke; Lieselotte Van Bockstal; Leon Luyten; Kim Luyckx; Emmanuel Bottieau; Pierre Dorny Journal: Euro Surveill Date: 2019-08
Authors: Deby Mukendi; Jean-Roger Lilo Kalo; Pascal Lutumba; Barbara Barbé; Jan Jacobs; Cedric P Yansouni; Sarah Gabriël; Pierre Dorny; François Chappuis; Marleen Boelaert; Andrea S Winkler; Kristien Verdonck; Emmanuel Bottieau Journal: BMC Infect Dis Date: 2021-04-17 Impact factor: 3.090
Authors: María Ángeles Gómez-Morales; Patrizio Pezzotti; Alessandra Ludovisi; Belgees Boufana; Pierre Dorny; Titia Kortbeek; Joachim Blocher; Veronika Schmidt; Marco Amati; Sarah Gabriël; Edoardo Pozio; Andrea Sylvia Winkler; The Ring Trial Participants Journal: Microorganisms Date: 2021-05-29